1. Medtech Insight
  2. >>Archive

FDA clears Mederi's new generator for Stretta and Secca systems

 
• By Madeleine Armstrong

The US FDA has granted 510(k) clearance for Mederi Therapeutics’ MDRF1 generator, which is used to power the firm’s Stretta and Secca systems. The former device is used to treat gastroesophageal reflux disease (GERD), while the latter treats bowel incontinence or bowel control disorder. Both devices use radiofrequency energy to remodel the valves or sphincters at either end of the digestive tract. The new generator is smaller, lighter and has a more intuitive user interface than its predecessors, Greenwich, Connecticut-based Mederi claims. Previously, the two devices were powered by two separate generators, so combining them into one could reduce costs, the company added. Mederi CE marked its next-generation Stretta and Secca systems in November (www.clinica.co.uk, 9 November 2010).

The US FDA has granted 510(k) clearance for Mederi Therapeutics’ MDRF1 generator, which is used to power the firm’s Stretta and Secca systems. The former device is used to treat gastroesophageal reflux disease (GERD), while the latter treats bowel incontinence or bowel control disorder. Both devices use radiofrequency energy to remodel the valves or sphincters at either end of the digestive tract. The new generator is smaller, lighter and has a more intuitive user interface than its predecessors, Greenwich, Connecticut-based Mederi claims. Previously, the two devices were powered by two separate generators, so combining them into one could reduce costs, the company added. Mederi CE marked its next-generation Stretta and Secca systems in November (www.clinica.co.uk, 9 November 2010).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Ryan Nelson

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Ryan Nelson

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By Marion Webb

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 
• By Natasha Barrow

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

Dxcover Launches US Operations With New Headquarters In Tennessee

 
• By Natasha Barrow

Dxcover sets up new Clinical Laboratory Improvement Amendments (CLIA) lab in Franklin, Tennessee.

EnsoData Boosts AI Sleep Tech With $20M Series B Funding, Targets Underdiagnosis Crisis

 
• By Shubham Singh

EnsoData positions itself as device-agnostic and interoperable, with FDA-cleared software that can integrate with all major devices. CEO Mortara said this flexibility helps maximize patient reach by enabling both direct provider engagement and integration with device manufacturers.

FDA Blocks Some Olympus Endoscopes From Entering US

 
• By Brian Bossetta

After multiple warning letters and safety communications, the US FDA has decided to block the import of certain endoscopes from Olympus. In total, the agency’s action pertains to 58 device models manufactured by the Japanese firm used in urinary, respiratory, abdominal and pelvic procedures.